IL1RL1 is upregulated in chronic myeloid leukemia (CML) cells by the fusion protein BCR-ABL and treatment with IL-33 promotes resistance to the BCR-ABL inhibitor imatinib23. Here, IL33 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.